Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

AIMS: Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20‐positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The pharmacokinetics and pharmacodynamics of ocrelizumab i...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Gibiansky, Ekaterina, Petry, Claire, Mercier, Francois, Günther, Andreas, Herman, Ann, Kappos, Ludwig, Hauser, Stephen, Yamamoto, Yumi, Wang, Qing, Model, Fabian, Kletzl, Heidemarie
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247316/
https://ncbi.nlm.nih.gov/pubmed/33202059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14658
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg